News

Under the terms of the agreement, Grifols to have worldwide exclusive commercial rights to Selagine’s treatment upon regulatory authorization, expected in early 2029.

Under the terms of the agreement, Grifols to have worldwide exclusive commercial rights to Selagine’s treatment upon regulatory authorization, expected in early 2029.

Alice Epitropoulos, MD, gives tips on how to optimize treatment for patients with meibomian gland dysfunction (MGD).

There are now treatments available that target VEGF to prevent vessel overgrowth, and they often provide dramatic benefits at first. Unfortunately, these benefits can fade with time.

Researchers have identified a new target to prevent the formation of abnormal tangles of blood vessels associated with eye conditions such as neovascular age-related macular degeneration, proliferative diabetic retinopathy and ischemic retinal vein occlusion.

The child's changes in vision began at school and worsened over the next day to the point where he could see only outlines and shapes of objects.

Researchers recommended that patients being treated with ethambutol should be screened regularly by an ophthalmologist for the early detection of optic neuropathy.

According to researchers, the treatment with botulinum toxin is safe, fast-acting, and improves both cosmetic appearance and quality of life, and could be considered as a choice for patients not opting for surgery.

Researchers conducted a retrospective analysis of longitudinal, clinical data from patients with high myopic MNV treated with intravitreal bevacizumab.

Cedars-Sinai investigators map changes to the retina that correspond to brain changes in the early stage, opening a path to earlier diagnosis.

Ophthalmologists could find themselves treating a growing number of young people who are applying lip balm to their eyelids, only to experience discomfort and vision issues when it gets into their eyes.

According to the company, post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months. The analysis will be presented at the ARVO Annual Meeting from April 23-27 in New Orleans.

According to researchers, patients with chronic CSC treated with 1 fovea-involving, half-dose PTD application had a significant improvement in structure and function at the final follow-up and foveal atrophy did not develop in any patients.

Key is to use stem cell treatments to ensure optimal outcomes for patients.

According to James Chodosh MD, MPH, some corneal conditions may not be treatable with a transplant.

Examining the anatomy and physiology may prevent ineffective stent implantation.

At the American Glaucoma Society meeting in Austin, Texas, the company presented findings demonstrating the safety and efficacy of its FLigHT treatment.

Primary vitreoretinal lymphoma is a rare, aggressive, and potentially fatal retinal cancer that is diagnosed in approximately 300 to 600 patients in the United States per year.

Priya M. Mathews, MD, MPH discusses ophthalmology and what she wishes she knew to start her career. As well as tips for other ophthalmologists who are just starting their careers.

Stromal regeneration seems possible in patients with keratoconus.

MCO-010 has been granted orphan drug designation by the FDA for both diseases and multiple mid- to late-stage clinical trials are ongoing.

According to the company, the award advances Praetego's lead candidate, PTG-630, into preclinical proof of concept in diabetic retinopathy.

The new laser will allow surgeons to perform refractive correction on patients with myopia, with or without astigmatism using the SILK Procedure.

The technology will be available soon for ophthalmologists in select countries across Asia Pacific and Europe.

Despite its promise, RGC replacement represents a more formidable challenge.

When tested, the recalled Artificial Tears used by the firefighter were found to contain large amounts of Pseudomonas Aeruginosa bacterial contamination.

Joel S. Schuman, MD, FACS, is a pioneer in the field of ophthalmology, lauded for his research, discoveries, inventions, and compassionate patient care over the course of his more than 30-year career.

The company is anticipating the first patient-first visit in Q1 2023 and is looking to release top-line data from the Phase 2 trial in Q4 2023.